Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AmerisourceBergen Corporation.

Latest From AmerisourceBergen Corporation.

Underwater: Medicare Negotiated Prices For Part B Cancer Drugs Could Change Prescribing

Anticipation that reimbursement for significantly discounted Keytruda and Opdivo won’t keep them afloat will influence treatment decisions by oncology providers, officials predict.

Medicare Reimbursement

Henlius Announces Positive Phase I/II Results For Ophthalmic Bevacizumab Biosimilar

Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.

Clinical Trials Biosimilars

The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow

While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.

Supply Chain Quality

How To Develop A Patient-First Strategy For CGT Commercialization

Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.

Gene Therapy Market Access
See All

Company Information

  • Industry
  • Distributors
  • Services